Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.190
-0.020 (-1.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.190
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Actinium Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Other Revenue | 0.09 | - | 0.08 | 1.03 | 1.14 | |
| Revenue | 0.09 | - | 0.08 | 1.03 | 1.14 | |
| Revenue Growth (YoY) | - | - | -92.14% | -9.96% | - | |
| Gross Profit | 0.09 | - | 0.08 | 1.03 | 1.14 | |
| Selling, General & Admin | 15.21 | 12.08 | 13.33 | 12 | 8.08 | |
| Research & Development | 21.12 | 30.05 | 38.67 | 23.14 | 18.03 | |
| Operating Expenses | 36.34 | 42.12 | 52 | 35.13 | 26.11 | |
| Operating Income | -36.25 | -42.12 | -51.92 | -34.1 | -24.96 | |
| Interest & Investment Income | 2.36 | 3.88 | 3.1 | 1.09 | 0.19 | |
| Pretax Income | -33.89 | -38.24 | -48.82 | -33.02 | -24.77 | |
| Net Income | -33.89 | -38.24 | -48.82 | -33.02 | -24.77 | |
| Net Income to Common | -33.89 | -38.24 | -48.82 | -33.02 | -24.77 | |
| Shares Outstanding (Basic) | 31 | 30 | 27 | 24 | 21 | |
| Shares Outstanding (Diluted) | 31 | 30 | 27 | 24 | 21 | |
| Shares Change (YoY) | 3.74% | 13.03% | 10.20% | 17.37% | 69.51% | |
| EPS (Basic) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | |
| EPS (Diluted) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | |
| Free Cash Flow | -24.68 | -33.08 | -47.49 | 8.28 | -21 | |
| Free Cash Flow Per Share | -0.79 | -1.10 | -1.78 | 0.34 | -1.02 | |
| Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -40274.44% | - | -64098.76% | -3311.07% | -2182.17% | |
| Profit Margin | -37652.22% | - | -60269.14% | -3205.53% | -2165.56% | |
| Free Cash Flow Margin | -27426.67% | - | -58627.16% | 803.69% | -1835.58% | |
| EBITDA | -36.06 | -41.91 | -51.71 | -33.9 | -24.78 | |
| D&A For EBITDA | 0.18 | 0.21 | 0.21 | 0.21 | 0.19 | |
| EBIT | -36.25 | -42.12 | -51.92 | -34.1 | -24.96 | |
| Revenue as Reported | 0.09 | - | 0.08 | 1.03 | 1.14 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.